{
  "id": 3703431,
  "title": "US drug agency approves breakthrough treatment for pancreatic cancer",
  "url": "https://urgent.news/2026/08/27/us-drug-agency-approves-breakthrough-treatment-for-pancreatic-cancer-3703431",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-27T08:03:02.000Z",
  "source": {
    "name": "Adom Online",
    "slug": "adom-online",
    "url": "https://www.adomonline.com/us-drug-agency-approves-breakthrough-treatment-for-pancreatic-cancer/"
  },
  "original_language": "en",
  "account": "The US Food and Drug Administration has granted approval to a groundbreaking treatment for pancreatic cancer, with clinical trials revealing a significant increase in patient survival rates. The drug, daraxonrasib, marketed as Rasonque, was developed by Revolution Medicines and demonstrated in a late-stage trial involving 500 individuals. Patients who took the daily medication exhibited an average survival time of 13.2 months, a stark contrast to the 6.6-month survival rate observed in those on chemotherapy. The FDA emphasized that daraxonrasib represents a \"critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer.\" The drug functions by inhibiting the mutated KRAS gene, which is present in over 90% of pancreatic tumors, thereby halting cancer growth. Pancreatic cancer claims the lives of approximately 67,000 Americans each year, boasting the highest mortality rate among major cancers. Typically diagnosed at a late stage, it is notoriously challenging to treat; more than half of patients succumb within three months of diagnosis. In 2025, the FDA classified daraxonrasib as a \"Breakthrough Therapy,\" an accolade reserved for treatments targeting serious conditions that merit expedited review. The agency expedited its approval by six months due to the drug's superior performance in addressing a severe unmet medical need. Common adverse effects of the treatment included rash, diarrhea, nausea, fatigue, and vomiting. Roughly 44% of patients on daraxonrasib experienced severe side effects, compared to 57.5% of those receiving chemotherapy. Notably, former US Senator Ben Sasse, who disclosed a Stage 4 pancreatic cancer diagnosis in December, is participating in a clinical trial for the drug, reporting its efficacy in reducing tumor size.",
  "summary": "The US Food and Drug Administration has approved a treatment for pancreatic cancer that, in clinical trials, nearly doubled the overall survival time for patients. The drug, daraxonrasib, sold under the brand name Rasonque and manufactured by Revolution Medicines, appears to be a breakthrough in treating one of the world’s deadliest cancers. A late-stage clinical […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}